Dr Sadakatsu Ikeda speaks to ecancer at the WIN 2019 Symposium in Paris about the rapidly changing landscape of precision medicine in Japan.

He explains that there has been recent approval for access to comprehensive genomic profiling in Japan, with between 5000 and 20,000 people per year expected to be available for this data capture.

Dr Ikeda also discusses the difficulties in accessing drugs following genomic sequencing due to the possible treatments being 'off-label'.